You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Engineering a unique antibody for patients with RA

    SBC: ABWIZ BIO INC            Topic: NIAID

    RA is one of the most common chronic autoimmune disorders that can lead to complete joint destruction and severe disability if untreated. There is no cure for RA and up to 50% of RA patients do not respond to anti-TNF therapies as circulating Th-17/IL-17 levels are highly elevated subsequent to TNF blockade. For this subset of RA patients, disruption of a novel pathway that impairs the synergy bet ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. EpiZode: Noninvasive Seizure Screening in Preclinical Models of Epilepsy

    SBC: SIGNAL SOLUTIONS, LLC            Topic: 100

    EpiZode: Noninvasive Seizure Screening in Preclinical Models of Epilepsy There is an urgent need for research into treatment options for epilepsy and other seizure disorders. Animal models are increasingly used to understand disease mechanisms and to screen promising therapeutic approaches. Animal epilepsy model use typically requires expensive and labor-intensive experimentation, with invasive EE ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease

    SBC: Planet Biotechnology Incorporated            Topic: NIAID

    Lyme disease (LD) is the most prevalent vector-borne disease in the United States, with up to 300,000 cases a year. LD is caused by several species of the spirochete bacteria Borrelia burgdorferi sensu lato (the Lyme borreliae), which are transmitted by ticks from animal (bird, rodent) reservoirs to human hosts. While a short course of antibiotics is usually effective in eliminating the bacteria a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. HBI-002 to Prevent Anthracycline-Related Cardiotoxicity

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: NHLBI

    PROJECT SUMMARY There is an urgent need for the development of approaches to prevent cardiotoxicity in cancer patients being treated with anthracyclines, an important class of drugs in the treatment of cancer (e.g. doxorubicin). Anthracycline treatment-related cardiotoxicity is a major clinical problem that severely impacts patient care and also limits dose and usage. More than a quarter of patien ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. HBI-002 to Treat Ulcerative Colitis

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: 300

    PROJECT SUMMARY There is an urgent need for the development of new approaches to treat patients suffering from Ulcerative Colitis (UC), which is estimated to impact approximately one million adults in the United States, leading to morbidity, heightened risk of cancer, and mortality. In multiple preclinical studies, we and others have defined the therapeutic potential of low-dose exogenous carbon m ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. High Density Cell Respirator (HDCR) for the production of vectors, viruses and vaccines

    SBC: XDemics Corporation            Topic: NCATS

    PROJECT SUMMARY/ABSTRACT This Phase I/II STTR Fast Track proposal responds to the call from the 2018/2019 NCATS SBIR/STTR Research Priorities to develop technologies so that “new treatments and cures for disease can be delivered to patients more quickly”. The production of life-altering gene editing vectors, cancer killing viruses, and life- saving vaccines currently depends on traditional cel ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. High speed Intraoperative Assessment of Breast Tumor Margin using MarginPAT

    SBC: Vibronix, Inc.            Topic: O

    After a breast conserving therapy histology is often performed to check whether the excised tumor specimen is surrounded by a sufficient amount of normal tissue If a positive margin is identified then a second operation will be performed Currently the re operation rate is which raises a need for intraoperative detection of residual cancers The current intraoperative tools for margin ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Image Analysis Tools for mpMRI Prostate Cancer Diagnosis Using PI-RADS

    SBC: Eigen Health Services LLC            Topic: 102

    Project Summary Prostate cancer is one of the most commonly occurring forms of cancer, accounting for 21% of all cancer in men. The Prostate Imaging Reporting and Data System (PI-RADS) aims to standardize reporting of prostate cancer using multi-parametric magnetic resonance imaging (mpMRI). However, the in-depth analysis, as demanded by PI-RADS, remains challenging due to the complexity and heter ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. improving Cas9 mediated homologous recombination in pluripotent stem cells

    SBC: Applied Stemcell, Inc.            Topic: 200

    DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system

    SBC: FasCure Therapeutics LLC            Topic: NIAID

    DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government